Antisense Inhibition of Prekallikrein to Control Hereditary Angioedema

Danny M. Cohn, Nicholas J. Viney, Lauré M. Fijen, Eugene Schneider, Veronica J. Alexander, Shuting Xia, Gwendolyn E. Kaeser, Charvi Nanavati, Brenda F. Baker, Richard S. Geary, Marcel Levi, Joost C. M. Meijers, Erik S. G. Stroes

Research output: Contribution to journalArticleAcademicpeer-review

28 Citations (Scopus)

Abstract

Hereditary angioedema is characterized by recurrent and unpredictable episodes of subcutaneous and mucosal swelling that can be life threatening. IONIS-PKK-LRx is a ligand-conjugated antisense oligonucleotide designed for receptor-mediated delivery to hepatocytes. In a compassionate-use pilot study, two patients with severe bradykinin-mediated angioedema were initially administered weekly subcutaneous injections of the unconjugated parent drug, IONIS-PKKRx, for 12 to 16 weeks, after which they received IONIS-PKK-LRx at a dose of 80 mg every 3 to 4 weeks for 7 to 8 months. Treatment was accompanied by a reduction in the angioedema attack rate. (Funded by Amsterdam UMC.).
Original languageEnglish
Pages (from-to)1242-1247
Number of pages6
JournalNew England journal of medicine
Volume383
Issue number13
DOIs
Publication statusPublished - 24 Sept 2020

Cite this